CSIMarket
 
Amarin Corp Plcuk  (NASDAQ: AMRN)
Other Ticker:  
 
 
Price: $0.5410 $-0.03 -5.353%
Day's High: $0.5868 Week Perf: -2.38 %
Day's Low: $ 0.54 30 Day Perf: -1.64 %
Volume (M): 1,002 52 Wk High: $ 1.36
Volume (M$): $ 542 52 Wk Avg: $0.72
Open: $0.57 52 Wk Low: $0.43



 Market Capitalization (Millions $) 222
 Shares Outstanding (Millions) 411
 Employees 1,650
 Revenues (TTM) (Millions $) 279
 Net Income (TTM) (Millions $) -39
 Cash Flow (TTM) (Millions $) -114
 Capital Exp. (TTM) (Millions $) 1

Amarin Corp Plcuk
Amarin Corporation plc is a biopharmaceutical company that develops and commercializes therapeutic products for the treatment of cardiovascular diseases. The company is based in Dublin, Ireland and its main trading venue is the NASDAQ stock exchange in New York.

Amarin has developed a proprietary technology platform called the VASCEPAe (icosapent ethyl) drug product, which is a prescription medicine that is FDA-approved for the treatment of adult patients with severe hypertriglyceridemia (triglyceride levels above 500 mg/dL). Hypertriglyceridemia is a condition where the levels of triglycerides in the blood are elevated, and this can be a risk factor for the development of cardiovascular diseases like heart attacks and strokes.

VASCEPAe is a highly purified omega-3 fatty acid product that has been shown in clinical trials to reduce triglyceride levels in patients with hypertriglyceridemia. It is also believed that VASCEPAe has other beneficial effects on the cardiovascular system, including reductions in inflammation and improvements in lipid profiles.

Amarin is also conducting research into the use of its omega-3 fatty acid technology for the treatment of other cardiovascular and metabolic diseases. The company has a pipeline of clinical development programs that are focused on a range of indications, including cardiovascular risk reduction in patients with statin therapy, chronic kidney disease, and diabetes mellitus.

Since its inception in 1993, Amarin has raised over $1 billion in funding through a combination of public offerings, private placements, and grants. The company has also entered into partnerships with several pharmaceutical companies, including Kowa Pharmaceuticals America, which is responsible for the commercialization of VASCEPAe in the US.

Despite facing competition from other omega-3 fatty acid products on the market, Amarin has been able to maintain a strong position in the hypertriglyceridemia treatment market due to the unique properties of VASCEPAe. The company's strong financial position and ongoing commitment to research and development make it an attractive investment opportunity for investors who are interested in the biopharmaceutical sector.


   Company Address: One Central Plaza Dublin 2
   Company Phone Number: 6699 020   Stock Exchange / Ticker: NASDAQ AMRN


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BGNE        1.21% 
BMY   -5.17%    
LLY        8.38% 
MRK   -12.54%    
PFE   -1.76%    
REGN        6.47% 
• View Complete Report
   



Product Service News

Navigating Challenges Amarin Secures VAZKEPAs Italian Reimbursement Amidst Market Lows,

Published Sun, Dec 29 2024 9:18 PM UTC

Amarin s Breakthrough with VAZKEPA Reimbursement in Italy Amidst Market Challenges Amarin Corporation, recognized globally for its novel pharmaceutical advancements, has received a national reimbursement approval in Italy for its significant drug, VAZKEPA (icosapent ethyl). This approval marks a critical milestone for Amarin as it seeks to expand its market presence across E...

Clinical Study

Latest Research Highlighting VASCEPA/VAZKEPA (icosapent ethyl) REDUCE-IT Subgroup Data and New Mechanistic Insights i...

Published Thu, Aug 22 2024 12:30 PM UTC

Subgroup Data and Mechanistic Insights of VASCEPA/VAZKEPA (Icosapent Ethyl) to Be Showcased at Major Cardiological Conferences in 2024Dublin, Ireland, and Bridgewater, N.J., August 22, 2024 Amarin Corporation plc (NASDAQ: AMRN) has announced the upcoming presentation of new subgroup data from the REDUCE-IT cardiovascular outcomes trial for VASCEPA?/VAZKEPA? (icosapent eth...

Product Service News

Amarins VAZKEPA Now Nationally Reimbursed in Portugal, Expanding Access to Effective Cardiovascular Disease Manageme...

Published Wed, Jul 17 2024 8:15 PM UTC

Amarin Receives National Reimbursement for VAZKEPA (icosapent ethyl) in PortugalThe Portuguese Ministry of Health has recently granted national reimbursement approval for VAZKEPA (icosapent ethyl), a medication designed to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD). This decision marks the eighth European country t...

Partnership

VASCEPA Receives Regulatory Approval in China, Ushering in a New Era of Cardiovascular Risk Reduction

Published Mon, Jul 8 2024 11:30 AM UTC

Amarin s Flagship Medication VASCEPA Receives Regulatory Approval in Mainland China, Paving the Way for Cardiovascular Risk ReductionIn a groundbreaking development, Amarin s strategic partner, EddingPharm, has received regulatory approval from the National Medical Products Administration (NMPA) for VASCEPA (Icosapent Ethyl) in Mainland China. The approval allows VASCEPA to ...

Product Service News

Breakthrough in Cardiovascular Care: Greece Grants National Reimbursement for Amarins ...

Published Tue, May 28 2024 12:15 PM UTC

Amarin s VAZKEPA Receives National Reimbursement in Greece, Expands European Market Presence with Exclusive Agreement with Vianex S.A.In a substantial development for Amarin Corporation, the Greek Ministry of Health has granted national reimbursement for VAZKEPA (icosapent ethyl), a prescription fish oil derivative, to reduce cardiovascular risk in statin-treated adult patie...







Amarin Plcuk's Segments





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com